Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Calliditas Therapeutics in connection with acquisition of controlling interest in Genkyotex SA
Mandate

Vinge advises Calliditas Therapeutics in connection with acquisition of controlling interest in Genkyotex SA

August 13, 2020 Capital Markets and Public M&A

Vinge advises Calliditas Therapeutics, a specialty pharmaceutical company listed on Nasdaq Stockholm and on The Nasdaq Global Select Market in the US, in connection with its acquisition of a controlling interest of 62.7% of the French company Genkyotex SA, a leader in NOX inhibition therapies and listed on Euronext Paris and Euronext Brussels.

Calliditas is seeking to acquire all outstanding Genkyotex shares and will following completion of the control transaction, which is expected to close in October 2020, launch a mandatory cash tender offer on the same terms for the remaining shares.

Vinge’s team comprises Dain Hård Nevonen, Sofie Bjärtun, Linnéa Sellström and Julia Hirschberg.





Related

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

 Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

 HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026

Vinge has advised SBP Kredit AB (publ) in connection a securitisation with a Nordic bank as senior lender

 The agreement covers a total amount of SEK 1 billion and creates conditions for significantly increased lending capacity. The agreement has been structured in accordance with the EU Securitisation Regulation and enables qualified loans to be continuously transferred to a special purpose vehicle within the SBP group.
September 14, 2026